Kainos Laboratories, Inc. (JP:4556)
:4556
Want to see JP:4556 full AI Analyst Report?
4556 Stock Chart & Stats
¥1271.00
¥2.00(0.16%)
At close: 4:00 PM EST
¥1271.00
¥2.00(0.16%)
Day’s Range― - ―
52-Week Range¥1,204.00 - ¥2,284.00
Previous CloseN/A
Volume2.10K
Average Volume (3M)3.67K
Market Cap
¥9.28B
Enterprise Value¥6.00B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)55.9
Beta0.54
Next Earnings
Jul 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.53%
Share Statistics
EPS (TTM)33.54
Shares Outstanding4,558,860
10 Day Avg. Volume3,280
30 Day Avg. Volume3,666
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.32
Price to Sales (P/S)1.75
P/FCF Ratio17.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity (~0.08) and an improving balance sheet provide durable financial flexibility. This reduces refinancing and solvency risk, supports investment or M&A optionality, and helps the company withstand cyclical stress without eroding long-term capital allocation.
Resilient Revenue GrowthConsistent mid-single-digit top-line growth demonstrates steady demand for the company's diagnostic products. Persistent revenue expansion underpins scale advantages and recurring sales, supporting predictable cash generation and strategic planning over the medium term.
Solid Gross MarginsA roughly 46% gross margin signals structural pricing power or efficient manufacturing for reagent/diagnostic products. Sustained gross margins create a buffer to absorb cost inflation and enable reinvestment in R&D or sales, supporting long-term profit potential if mix and pricing hold.
Bears Say
Margin CompressionA significant decline in operating and net margins points to either rising costs, weaker pricing, or adverse mix that can persist. Lower margins reduce retained earnings and capital available for growth or distribution, and may reflect structural competitive or cost pressures.
Weaker Free Cash Flow / Cash ConversionDeclining free cash flow and a marked drop in cash conversion versus profits signal volatility in working capital or timing of investments. This undermines reliable internal funding for capex, R&D, or dividends and increases reliance on external financing for strategic initiatives.
Cooling Returns On EquityA sustained decline in ROE to the low single digits indicates weakening capital efficiency and slower equity compounding. Persistently lower ROE can constrain shareholder returns and may reflect structural margin or growth challenges that hinder long-term value creation.
4556 FAQ
What was Kainos Laboratories, Inc.’s price range in the past 12 months?
Kainos Laboratories, Inc. lowest stock price was ¥1204.00 and its highest was ¥2284.00 in the past 12 months.
What is Kainos Laboratories, Inc.’s market cap?
Kainos Laboratories, Inc.’s market cap is ¥9.28B.
When is Kainos Laboratories, Inc.’s upcoming earnings report date?
Kainos Laboratories, Inc.’s upcoming earnings report date is Jul 27, 2026 which is in 46 days.
How were Kainos Laboratories, Inc.’s earnings last quarter?
Kainos Laboratories, Inc. released its earnings results on May 08, 2026. The company reported ¥33.54 earnings per share for the quarter, beating the consensus estimate of N/A by ¥33.54.
Is Kainos Laboratories, Inc. overvalued?
According to Wall Street analysts Kainos Laboratories, Inc.’s price is currently Overvalued.
Does Kainos Laboratories, Inc. pay dividends?
Kainos Laboratories, Inc. pays a Annually dividend of ¥32 which represents an annual dividend yield of 2.53%. See more information on Kainos Laboratories, Inc. dividends here
What is Kainos Laboratories, Inc.’s EPS estimate?
Kainos Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kainos Laboratories, Inc. have?
Kainos Laboratories, Inc. has 4,558,860 shares outstanding.
What happened to Kainos Laboratories, Inc.’s price movement after its last earnings report?
Kainos Laboratories, Inc. reported an EPS of ¥33.54 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kainos Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:4556
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kainos Laboratories, Inc.
Based in Tokyo, Japan, KAINOS Laboratories, Inc. specializes in the research, development, production, commercialization, and global trade of various items. Its extensive portfolio encompasses pharmaceuticals, diagnostic agents, and associated chemical compounds, alongside scientific measurement devices, medical provisions, nutritional supplements, food products, and animal feed. Among its key offerings are biochemical clinical testing reagents like the Aqua-auto Kainos CRE-IV, ALB, and UN-II Test Kits, designed for detecting creatinine, albumin, and urea nitrogen, respectively, across diverse automatic analyzer systems. The company also supplies the FGF-23 ELISA Kit for quantifying FGF-23 in serum samples. Furthermore, KAINOS provides rapid diagnostic solutions for on-site use, including Swiftgene Norovirus GI/GII Kainos for norovirus detection, Statmark FLUstick II for influenza virus antigens (types A and B), and Statmark Strep A for Group A beta-hemolytic streptococci. Established in 1975, the company assumed its current identity, KAINOS Laboratories, Inc., in July of that year, having previously operated under the name DOMS-IATRON Co., Ltd.